CL2017002116A1 - Dosis de panobinostat para el mieloma múltiple. - Google Patents

Dosis de panobinostat para el mieloma múltiple.

Info

Publication number
CL2017002116A1
CL2017002116A1 CL2017002116A CL2017002116A CL2017002116A1 CL 2017002116 A1 CL2017002116 A1 CL 2017002116A1 CL 2017002116 A CL2017002116 A CL 2017002116A CL 2017002116 A CL2017002116 A CL 2017002116A CL 2017002116 A1 CL2017002116 A1 CL 2017002116A1
Authority
CL
Chile
Prior art keywords
panobinostat
multiple myeloma
dose
bortezomib
safety
Prior art date
Application number
CL2017002116A
Other languages
English (en)
Inventor
Rong Lin
Song Mu
Sofia Paul
Laura Grazioli
Renaud Capdeville
Florence Binlich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55405393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017002116A1 publication Critical patent/CL2017002116A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<p>Tratamiento de mieloma múltiple con una combinación de panobinostat y bortezomib con dosis especificadas ajustadas para Ia seguridad.</p>
CL2017002116A 2015-02-19 2017-08-18 Dosis de panobinostat para el mieloma múltiple. CL2017002116A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562118254P 2015-02-19 2015-02-19
US201562119571P 2015-02-23 2015-02-23

Publications (1)

Publication Number Publication Date
CL2017002116A1 true CL2017002116A1 (es) 2018-05-18

Family

ID=55405393

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002116A CL2017002116A1 (es) 2015-02-19 2017-08-18 Dosis de panobinostat para el mieloma múltiple.

Country Status (19)

Country Link
US (3) US20190388393A1 (es)
EP (1) EP3258933A1 (es)
JP (2) JP2018507216A (es)
KR (1) KR20170118798A (es)
CN (1) CN107249596A (es)
AU (2) AU2016221327A1 (es)
BR (1) BR112017017594A2 (es)
CA (1) CA2976755A1 (es)
CL (1) CL2017002116A1 (es)
IL (1) IL253895A0 (es)
MA (1) MA41544A (es)
MX (1) MX2017010577A (es)
PH (1) PH12017501494A1 (es)
RU (1) RU2729425C2 (es)
SG (1) SG11201706521XA (es)
TN (1) TN2017000356A1 (es)
TW (1) TW201630602A (es)
WO (1) WO2016132303A1 (es)
ZA (1) ZA201705363B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314222B (zh) * 2019-08-07 2023-05-26 上海交通大学医学院附属瑞金医院 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0614090A2 (pt) * 2005-08-03 2011-03-09 Novartis Ag uso de inibidores da hdac para o tratamento do mieloma
MX2008015901A (es) 2006-06-12 2009-01-12 Novartis Ag Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]met il]fenil]-2e-2-propenamida.
AU2008216327A1 (en) * 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8263578B2 (en) * 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
KR20160006668A (ko) * 2013-03-14 2016-01-19 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물

Also Published As

Publication number Publication date
PH12017501494A1 (en) 2018-01-29
KR20170118798A (ko) 2017-10-25
IL253895A0 (en) 2017-10-31
MX2017010577A (es) 2017-12-07
US20190388393A1 (en) 2019-12-26
RU2017132445A (ru) 2019-03-20
CN107249596A (zh) 2017-10-13
AU2016221327A1 (en) 2017-08-31
SG11201706521XA (en) 2017-09-28
RU2017132445A3 (es) 2019-09-23
CA2976755A1 (en) 2016-08-25
ZA201705363B (en) 2019-07-31
EP3258933A1 (en) 2017-12-27
US20200093795A1 (en) 2020-03-26
RU2729425C2 (ru) 2020-08-06
JP2021105048A (ja) 2021-07-26
AU2019200876A1 (en) 2019-02-28
MA41544A (fr) 2017-12-26
US20230181529A1 (en) 2023-06-15
WO2016132303A1 (en) 2016-08-25
JP2018507216A (ja) 2018-03-15
TW201630602A (zh) 2016-09-01
AU2019200876B2 (en) 2020-05-28
BR112017017594A2 (pt) 2018-05-08
TN2017000356A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
DOP2016000233A (es) MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B
CO2017001994A2 (es) Compuestos activos hacia bromodominios
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
CO2018000224A2 (es) Compuestos inhibidores de la señalización de la vía de notch
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
CL2017000050A1 (es) Terapia de combinación para el cáncer
TW201713333A (en) Methods of treating a neurodegenerative disease
BR112017008481A2 (pt) composto antimicótico
TWD180966S (zh) 安全注射器
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
EA201890828A1 (ru) Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин
CL2018001434A1 (es) Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
AR102871A1 (es) Métodos de tratamiento de fibrosis
AR105595A1 (es) PROCEDIMIENTO PARA EL TRATAMIENTO DE ENFERMEDADES INFECCIOSAS UTILIZANDO UNA COMPOSICIÓN QUE COMPRENDE INMUNOGLOBULINA M (IgM) DERIVADA DE PLASMA